A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma
Phase 2
Completed
- Conditions
- Multiple Myeloma
- Registration Number
- NCT00051116
- Lead Sponsor
- Celgene Corporation
- Brief Summary
To evaluate the response rate, response duration, and survival of patients treated with CC-5013 in a chronic dosing schedule versus a syncopated dosing schedule.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Myeloma Institute University of Arkansas for Medical Sciences
🇺🇸Little Rock, Arkansas, United States
Myeloma Institute University of Arkansas for Medical Sciences🇺🇸Little Rock, Arkansas, United States